These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 1322857)
21. Effects of long-term oral administration of NZ-105, a novel calcium antagonist, with or without propranolol in spontaneously hypertensive rats. Shudo C; Masuda Y; Sakai T; Tanaka S; Shigenobu K; Kasuya Y J Pharm Pharmacol; 1993 Jun; 45(6):525-9. PubMed ID: 8103100 [TBL] [Abstract][Full Text] [Related]
22. An antibody to dihydropyridine calcium entry blockers. A comparison with the calcium channel receptor in skeletal muscle. Thayer SA; Pham DH; Schultz CM; Minaskanian G; Fairhurst AS Biochem Pharmacol; 1986 Dec; 35(24):4479-85. PubMed ID: 3024651 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo characterization of 2,6-dimethyl-3,5-dicarbomethoxy-4-(2-isothiocyano)phenyl-1,4- dihydropy ridine as a Ca2+ channel antagonist. Gengo P; Su CM; Yousif FB; Triggle DJ Can J Physiol Pharmacol; 1987 Dec; 65(12):2472-82. PubMed ID: 3449204 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological activity of novel calcium channel blockers: 2,5-dihydro-4-methyl-2-phenyl-1,5-benzothiazepine-3-carboxylic acid esters and 2,5-dihydro-4-methyl-2-phenyl-1,5-benzodiazepine-3-carboxylic acid esters. Atwal KS; Bergey JL; Hedberg A; Moreland S J Med Chem; 1987 Apr; 30(4):635-40. PubMed ID: 2435903 [TBL] [Abstract][Full Text] [Related]
25. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats. Uchida S; Yamada S; Ohkura T; Heshikiri M; Yoshimi A; Shirahase H; Kimura R Br J Pharmacol; 1995 Jan; 114(1):217-23. PubMed ID: 7712021 [TBL] [Abstract][Full Text] [Related]
26. Analysis of the properties of binding of calcium-channel activators and inhibitors to dihydropyridine receptors in chick heart membranes. Maan AC; Hosey MM Circ Res; 1987 Sep; 61(3):379-88. PubMed ID: 2441891 [TBL] [Abstract][Full Text] [Related]
27. Competitive binding experiments reveal differential interactions for dihydropyridine calcium channel activators and antagonists at dihydropyridine receptors on mouse brain membranes. O'Neill SK; Triggle CR; Bolger GT Can J Physiol Pharmacol; 1994 Jul; 72(7):738-45. PubMed ID: 7530159 [TBL] [Abstract][Full Text] [Related]
28. Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Qu YL; Sugiyama K; Nagatomo T; Maniwa T; Miyagishi A Jpn J Pharmacol; 1993 Oct; 63(2):165-9. PubMed ID: 8283826 [TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity. Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y J Pharm Pharmacol; 1993 Jun; 45(6):530-4. PubMed ID: 7689649 [TBL] [Abstract][Full Text] [Related]
30. o-Isothiocyanate dihydropyridine (oNCS-DHP), a long-acting, reversible inhibitor of the Ca++ channel. Kozlowski R; Ehrhard P; Fischli W; Osterrieder W; Holck M J Pharmacol Exp Ther; 1986 Sep; 238(3):1084-91. PubMed ID: 2427686 [TBL] [Abstract][Full Text] [Related]
31. Receptor model for the molecular basis of tissue selectivity of 1, 4-dihydropyridine calcium channel drugs. Langs DA; Strong PD; Triggle DJ J Comput Aided Mol Des; 1990 Sep; 4(3):215-30. PubMed ID: 2177783 [TBL] [Abstract][Full Text] [Related]
32. [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex. Schoemaker H; Langer SZ Eur J Pharmacol; 1985 May; 111(2):273-7. PubMed ID: 2410283 [TBL] [Abstract][Full Text] [Related]
33. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619 [TBL] [Abstract][Full Text] [Related]
34. Characterization of the binding sites for nimodipine and (-)-desmethoxyverapamil in bovine cardiac sarcolemma. Ruth P; Flockerzi V; von Nettelbladt E; Oeken J; Hofmann F Eur J Biochem; 1985 Jul; 150(2):313-22. PubMed ID: 2990931 [TBL] [Abstract][Full Text] [Related]
35. [35S]sadopine, a novel high affinity, high specific activity, L-type Ca2+ channel probe: characterization of two equipotent diastereomers with opposite allosteric properties. Knaus HG; Striessnig J; Hering S; Marrer S; Schwenner E; Höltje HD; Glossmann H Mol Pharmacol; 1992 Feb; 41(2):298-307. PubMed ID: 1311409 [TBL] [Abstract][Full Text] [Related]
36. [Effect of efonidipine hydrochloride (NZ-105) on modification of low density lipoprotein induced by rat cultured endothelial cells]. Ito S; Higashino R; Tanaka T; Takei M; Kurimoto T; Matsuda K Nihon Yakurigaku Zasshi; 1995 Oct; 106(4):263-70. PubMed ID: 8537073 [TBL] [Abstract][Full Text] [Related]
37. Identification of dihydropyridine (DHP) binding sites on cultured monkey renal cells (GMRC) with a photoaffinity probe (-)-[3H]-azidopine. Drímal J Gen Physiol Biophys; 1994 Apr; 13(2):137-48. PubMed ID: 7528701 [TBL] [Abstract][Full Text] [Related]
38. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036 [TBL] [Abstract][Full Text] [Related]
39. Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain. Morel N; Godfraind T Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):442-51. PubMed ID: 2555723 [TBL] [Abstract][Full Text] [Related]
40. The effect of photogenerated site-directed free radicals on surface dihydropyridine binding sites identified with photoaffinity probe (-)-[3H]-azidopine on cultured monkey renal cells. Drímal J; Bohácik L Methods Find Exp Clin Pharmacol; 1994; 16(6):397-404. PubMed ID: 7530790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]